Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
3,174
Views
27
CrossRef citations to date
0
Altmetric
Original Research

Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies

Zhenyu Huoa Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;b Nanshan School, Guangzhou Medical University, Guangzhou, ChinaORCID Iconhttps://orcid.org/0000-0002-9841-5081View further author information
ORCID Icon,
Caichen Lia Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Xin Xuc Department of Transplantation, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Fan Gea Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;d First Clinical School, Guangzhou Medical University, Guangzhou, ChinaORCID Iconhttps://orcid.org/0000-0002-6599-8807View further author information
ORCID Icon,
Runchen Wanga Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;b Nanshan School, Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Yaokai Wena Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;b Nanshan School, Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Haoxin Penga Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;b Nanshan School, Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Xiangrong Wua Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;b Nanshan School, Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Hengrui Lianga Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Guilin Penga Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;c Department of Transplantation, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Run Lia Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;c Department of Transplantation, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Danxia Huanga Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;c Department of Transplantation, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Ying Chena Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;c Department of Transplantation, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Ran Zhonga Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Bo Chenga Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Shan Xionga Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Weiyi Lind First Clinical School, Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Jianxing Hea Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1737-8192View further author information
ORCID Icon &
Wenhua Lianga Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1391-8238View further author information
ORCID Icon show all
Article: 1848068 | Received 11 Sep 2020, Accepted 06 Nov 2020, Published online: 29 Nov 2020

References

  • Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation. 2009;87(6):785–10.doi: 10.1097/TP.0b013e3181952623.
  • Charlton M, Levitsky J, Aqel B, OʼGrady J, Hemibach J, Rinella M, Fung J, Ghabril M, Thomason R, Burra P, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 2018;102(5):727–743. doi:10.1097/TP.0000000000002147.
  • Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009;125(8):1747–1754. doi:10.1002/ijc.24439.
  • Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther. 2008;8(4):605–615. doi:10.1586/14737140.8.4.605.
  • Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67. doi:10.1016/S0140-6736(07)61050-2.
  • Guba M, Graeb C, Jauch K-W, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation. 2004;77(12):1777–1782. doi:10.1097/01.TP.0000120181.89206.54.
  • Krynitz B, Edgren G, Lindelöf B, Baecklund E, Brattström C, Wilczek H, Smedby KE. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008–a Swedish population-based study. Int J Cancer. 2013;132(6):1429–1438. doi:10.1002/ijc.27765.
  • Engels EA, Pfeiffer RM, Fraumeni JF Jr., Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–1901. doi:10.1001/jama.2011.1592.
  • Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017 Apr 19;9(1):34. doi:10.1186/s13073-017-0424-2.
  • Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj. 2009 Jul;21(339):b2535. doi:10.1136/bmj.b2535.
  • Wells G. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta-analyses. 2001.
  • DerSimonian R, Laird N. Meta-analysis in clinical trials.  Control Clin Trials. 1986;7(3):177–188.
  • Ades A, Lu G, Higgins JJMDM. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25(6):646–654.
  • Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327(7414):557–560.
  • Begg CB, Mazumdar MJB. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994. p. 1088–1101.
  • Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629–634.
  • Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, Ekbom A, Adami H-O, Granath F. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–1227. doi:10.1038/sj.bjc.6601219.
  • Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010;10(8):1889–1896. doi:10.1111/j.1600-6143.2010.03181.x.
  • Hortlund M, Arroyo Mühr LS, Storm H, Engholm G, Dillner J, Bzhalava D. Cancer risks after solid organ transplantation and after long-term dialysis. Int J Cancer. 2017;140(5):1091–1101. doi:10.1002/ijc.30531.
  • Na R, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. Comparison of De Novo cancer incidence in australian liver, heart and lung transplant recipients. Am J Transplant. 2013;13(1):174–183. doi:10.1111/j.1600-6143.2012.04302.x.
  • O'Neill JP, Sexton DJ, O'Leary E, O'Kelly P, Murray S, Deady S, Daly F, Williams Y, Dean B, Fitzgerald C, et al. Post-transplant malignancy in solid organ transplant recipients in Ireland, the Irish transplant cancer group. Clin Transplant. 2019;33(10):e13669–e13669.
  • Park B, Yoon J, Choi D, Kim HJ, Jung YK, Kwon OJ, Lee KG. De novo cancer incidence after kidney and liver transplantation: results from a nationwide population based data. Sci Rep. 2019;9(1):17202. doi:10.1038/s41598-019-53163-9.
  • Serraino D, Piselli P, Busnach G, Burra P, Citterio F, Arbustini E, Baccarani U, De Juli E, Pozzetto U, Bellelli S, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer. 2007;43(14):2117–2123. doi:10.1016/j.ejca.2007.07.015.
  • Tsai H-I, Lee C-W, Kuo C-F, See L-C, Liu F-C, Chiou M-J, Yu H-P. De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study. Oncotarget. 2017;8(22):36685–36695. doi:10.18632/oncotarget.13124.
  • Wareham NE, Li Q, Sengeløv H, Da Cunha-Bang C, Gustafsson F, Heilmann C, Perch M, Rasmussen A, Sørensen SS, Mocroft A, et al. Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2019;145(12):3125–3135. doi:10.1007/s00432-019-03039-2.
  • Agraharkar ML, Cinclair RD, Kuo Y-F, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int. 2004;66(1):383–389. doi:10.1111/j.1523-1755.2004.00741.x.
  • Birkeland SA, L⊘kkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet. 2000;355(9218):1886–1887. doi:10.1016/S0140-6736(00)02298-4.
  • Buxeda A, Redondo-Pachón D, Pérez-Sáez MJ, Bartolomé Á, Mir M, Pascual-Dapena A, Sans A, Duran X, Crespo M, Pascual J, et al. Gender differences in cancer risk after kidney transplantation. Oncotarget. 2019;10(33):3114–3128. doi:10.18632/oncotarget.26859.
  • Cheung CY, Lam MF, Chu KH, Chow KM, Tsang KY, Yuen SK, Wong PN, Chan SK, Leung KT, Chan CK, et al. Malignancies after kidney transplantation: Hong Kong renal registry. Am J Transplant. 2012;12(11):3039–3046. doi:10.1111/j.1600-6143.2012.04209.x.
  • Heo J, Noh OK, Oh Y-T, Chun M, Kim L. Cancer risk after renal transplantation in South Korea: a nationwide population-based study. BMC Nephrol. 2018;19(1):311. doi:10.1186/s12882-018-1110-3.
  • Hoshida Y, Tsukuma H, Yasunaga Y, Xu N, Fujita MQ, Satoh T, Ichikawa Y, Kurihara K, Imanishi M, Matsuno T, et al. Cancer risk after renal transplantation in Japan. Int J Cancer. 1997;71(4):517–520. doi:10.1002/(SICI)1097-0215(19970516)71:4<517::AID-IJC3>3.0.CO;2-X.
  • Kessler M, Jay N, Molle R, Guillemin F. Excess risk of cancer in renal transplant patients. Transpl Int. 2006;19(11):908–914. doi:10.1111/j.1432-2277.2006.00383.x.
  • Kim JH, Kim S-O, Han DJ, Park S-K. Post-transplant malignancy: a burdensome complication in renal allograft recipients in Korea. Clin Transplant. 2014;28(4):434–442. doi:10.1111/ctr.12328.
  • Kyllönen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transpl Int. 2000;13(Suppl 1):S394–S398. doi:10.1111/j.1432-2277.2000.tb02068.x.
  • Li W-H, Chen Y-J, Tseng W-C, Lin M-W, Chen T-J, Chu S-Y, Hwang C-Y, Chen -C-C, Lee -D-D, Chang Y-T, et al. Malignancies after renal transplantation in Taiwan: a nationwide population-based study. Nephrol Dial Transplant. 2012;27(2):833–839. doi:10.1093/ndt/gfr277.
  • Mazzucotelli V, Piselli P, Verdirosi D, Cimaglia C, Cancarini G, Serraino D, Sandrini S. De novo cancer in patients on dialysis and after renal transplantation: north-western Italy, 1997–2012. J Nephrol. 2017;30(6):851–857. doi:10.1007/s40620-017-0385-y.
  • Opelz G, Unterrainer C, Süsal C, Döhler B. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients. Nephrol Dial Transplant. 2016;31(8):1360–1367. doi:10.1093/ndt/gfw088.
  • Piselli P, Serraino D, Segoloni GP, Sandrini S, Piredda GB, Scolari MP, Rigotti P, Busnach G, Messa P, Donati D, et al. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer. 2013;49(2):336–344. doi:10.1016/j.ejca.2012.09.013.
  • Ramsey-Goldman R, Brar A, Richardson C, Salifu MO, Clarke A, Bernatsky S, Stefanov DG, Jindal RM. Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients. Lupus Sci Med. 2016;3(1):e000156–e000156. doi:10.1136/lupus-2016-000156.
  • Schrem H, Schneider V, Kurok M, Goldis A, Dreier M, Kaltenborn A, Gwinner W, Barthold M, Liebeneiner J, Winny M. Independent pre-transplant recipient cancer risk factors after kidney transplantation and the utility of G-Chart analysis for clinical process control. PLoS One. 2016;11(7):e0158732–e0158732. doi:10.1371/journal.pone.0158732.
  • Teo SH, Lee KG, Lim GH, Koo SX, Ramirez ME, Chow KY, Kee T. Incidence, risk factors and outcomes of malignancies after kidney transplantation in Singapore: a 12-year experience. Singapore Med J. 2019;60(5):253–259. doi:10.11622/smedj.2018122.
  • Tessari G, Naldi L, Boschiero L, Minetti E, Sandrini S, Nacchia F, Valerio F, Rugiu C, Sassi F, Gotti E, et al. Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. Am J Transplant. 2013;13(1):214–221. doi:10.1111/j.1600-6143.2012.04294.x.
  • Vajdic CM, McDonald SP, McCredie MRE, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–2831. doi:10.1001/jama.296.23.2823.
  • Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007;7(4):941–948. doi:10.1111/j.1600-6143.2007.01736.x.
  • Aberg F, Pukkala E, Höckerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl. 2008;14(10):1428–1436.
  • Baccarani U, Piselli P, Serraino D, Adani GL, Lorenzin D, Gambato M, Buda A, Zanus G, Vitale A, De Paoli A, et al. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis. 2010;42(1):55–60. doi:10.1016/j.dld.2009.04.017.
  • Chatrath H, Berman K, Vuppalanchi R, Slaven J, Kwo P, Tector AJ, Chalasani N, Ghabril M. De novo malignancy post-liver transplantation: a single center, population controlled study. Clin Transplant. 2013 Jul-Aug;27(4):582–590. doi:10.1111/ctr.12171.
  • Ettorre GM, Piselli P, Galatioto L, Rendina M, Nudo F, Sforza D, Miglioresi L, Fantola G, Cimaglia C, Vennarecci G, et al. De novo malignancies following liver transplantation: results from a multicentric study in central and southern Italy, 1990–2008. Transplant Proc. 2013;45(7):2729–2732. doi:10.1016/j.transproceed.2013.07.050.
  • Heo J, Noh OK, Oh Y-T, Chun M, Kim L. Second primary cancer after liver transplantation in hepatocellular carcinoma: a nationwide population-based study. Hepatol Int. 2017;11(6):523–528. doi:10.1007/s12072-017-9824-z.
  • Hsiao C-Y, Lee P-H, Ho C-M, Wu Y-M, Ho M-C, Hu R-H. Post-transplant malignancy in liver transplantation: a single center experience. Medicine (Baltimore). 2014;93(28):e310–e310. doi:10.1097/MD.0000000000000310.
  • Jiang Y, Villeneuve PJ, Fenton SSA, Schaubel DE, Lilly L, Mao Y. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl. 2008;14(11):1588–1597. doi:10.1002/lt.21554.
  • Kaneko J, Sugawara Y, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, Yamashiki N, Kokudo N. De novo malignancies after adult-to-adult living-donor liver transplantation with a malignancy surveillance program: comparison with a Japanese population-based study. Transplantation. 2013;95(9):1142–1147. doi:10.1097/TP.0b013e318288ca83.
  • Maggi U, Consonni D, Manini MA, Gatti S, Cuccaro F, Donato F, Conte G, Bertazzi PA, Rossi G. Early and late de novo tumors after liver transplantation in adults: the late onset of bladder tumors in men. PLoS One. 2013;8(6):e65238–e65238. doi:10.1371/journal.pone.0065238.
  • Nordin A, Åberg F, Pukkala E, Pedersen CR, Storm HH, Rasmussen A, Bennet W, Olausson M, Wilczek H, Ericzon B-G, et al. Decreasing incidence of cancer after liver transplantation-A Nordic population-based study over 3 decades. Am J Transplant. 2018;18(4):952–963. doi:10.1111/ajt.14507.
  • Oo YH, Gunson BK, Lancashire RJ, Cheng KK, Neuberger JM. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation. 2005;80(6):759–764. doi:10.1097/01.TP.0000173775.16579.18.
  • Schrem H, Kurok M, Kaltenborn A, Vogel A, Walter U, Zachau L, Manns MP, Klempnauer J, Kleine M. Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection. Liver Transpl. 2013;19(11):1252–1261. doi:10.1002/lt.23722.
  • Sérée O, Altieri M, Guillaume E, De Mil R, Lobbedez T, Robinson P, Segol P, Salamé E, Abergel A, Boillot O. Longterm risk of solid organ De Novo malignancies after liver transplantation: A French national study on 11,226 patients. Liver Transpl. 2018;24(10):1425–1436. doi:10.1002/lt.25310.
  • Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, Emre S, Fishbein TM, Guy SR, Schwartz ME, et al. Long-term medical complications in patients surviving ???5 years after liver transplant. Transplantation. 2000;69(5):781–789. doi:10.1097/00007890-200003150-00018.
  • Taborelli M, Piselli P, Ettorre GM, Lauro A, Galatioto L, Baccarani U, Rendina M, Shalaby S, Petrara R, Nudo F, et al. Risk of virus and non-virus related malignancies following immunosuppression in a cohort of liver transplant recipients. Italy, 1985–2014. Int J Cancer. 2018;143(7):1588–1594.
  • Jäämaa-Holmberg S, Salmela B, Lemström K, Pukkala E, Lommi J. Cancer incidence and mortality after heart transplantation – A population-based national cohort study. Acta Oncol. 2019;58(6):859–863. doi:10.1080/0284186X.2019.1580385.
  • Jiang Y, Villeneuve PJ, Wielgosz A, Schaubel DE, Fenton SSA, Mao Y. The incidence of cancer in a population-based cohort of Canadian heart transplant recipients. Am J Transplant. 2010;10(3):637–645. doi:10.1111/j.1600-6143.2009.02973.x.
  • Kellerman L, Neugut A, Burke B, Mancini D. Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. Am J Cardiol. 2009;103(4):562–566. doi:10.1016/j.amjcard.2008.10.026.
  • Jensen AO, Svaerke C, Farkas D, Pedersen L, Kragballe K, Sørensen HT. Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol. 2010;90(5):474–479. doi:10.2340/00015555-0919.
  • Koshiol J, Pawlish K, Goodman MT, McGlynn KA, Engels EA. Risk of hepatobiliary cancer after solid organ transplant in the United States. Clin Gastroenterol Hepatol. 2014;12(9):1541–9.e3. doi:10.1016/j.cgh.2013.12.018.
  • Krynitz B, Olsson H, Lundh Rozell B, Lindelöf B, Edgren G, Smedby KE. Risk of basal cell carcinoma in Swedish organ transplant recipients: a population-based study. Br J Dermatol. 2016;174(1):95–103. doi:10.1111/bjd.14153.
  • Mahale P, Shiels MS, Lynch CF, Engels EA. Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients. Am J Transplant. 2018;18(2):453–461. doi:10.1111/ajt.14465.
  • Park MJ, Roh J-L, Choi S-H, Nam SY, Kim SY, Lee YS. De novo head and neck cancer arising in solid organ transplantation recipients: the Asan medical center experience. Auris Nasus Larynx. 2018;45(4):838–845. doi:10.1016/j.anl.2017.11.006.
  • Quinlan SC, Landgren O, Morton LM, Engels EA. Hodgkin lymphoma among US solid organ transplant recipients. Transplantation. 2010;90(9):1011–1015. doi:10.1097/TP.0b013e3181f5c3a6.
  • Rizvi SMH, Aagnes B, Holdaas H, Gude E, Boberg KM, Bjørtuft Ø, Helsing P, Leivestad T, Møller B, Gjersvik P. Long-term change in the risk of skin cancer after organ transplantation: a population-based nationwide cohort study. JAMA Dermatol. 2017;153(12):1270–1277. doi:10.1001/jamadermatol.2017.2984.
  • Robbins HA, Clarke CA, Arron ST, Tatalovich Z, Kahn AR, Hernandez BY, Paddock L, Yanik EL, Lynch CF, Kasiske BL, et al. Melanoma risk and survival among organ transplant recipients. J Invest Dermatol. 2015;135(11):2657–2665. doi:10.1038/jid.2015.312.
  • Safaeian M, Robbins HA, Berndt SI, Lynch CF, Fraumeni JF, Engels EA. Risk of colorectal cancer after solid organ transplantation in the United States. Am J Transplant. 2016;16(3):960–967. doi:10.1111/ajt.13549.
  • Kalinova L, Majek O, Stehlik D, Krejci K, Bachleda P. Skin cancer incidence in renal transplant recipients - a single center study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010;154(3):257–260. doi:10.5507/bp.2010.039.
  • Karami S, Yanik EL, Moore LE, Pfeiffer RM, Copeland G, Gonsalves L, Hernandez BY, Lynch CF, Pawlish K, Engels EA. Risk of renal cell carcinoma among kidney transplant recipients in the United States. Am J Transplant. 2016;16(12):3479–3489. doi:10.1111/ajt.13862.
  • Mäkitie AA, Lundberg M, Salmela K, Kyllönen L, Pukkala E. Head and neck cancer in renal transplant patients in Finland. Acta Otolaryngol. 2008;128(11):1255–1258. doi:10.1080/00016480801901725.
  • Medani S, O'Kelly P, O'Brien KM, Mohan P, Magee C, Conlon P. Bladder cancer in renal allograft recipients: risk factors and outcomes. Transplant Proc 2014;46(10):3466-3473.
  • Ekstrom M, Riise GC, Tanash HA. Risk of cancer after lung transplantation for COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2841–2847. doi:10.2147/COPD.S147065.
  • Fink AK, Yanik EL, Marshall BC, Wilschanski M, Lynch CF, Austin AA, Copeland G, Safaeian M, Engels EA. Cancer risk among lung transplant recipients with cystic fibrosis. J Cystic Fibrosis**. 2017 Jan;16(1):91–97. doi:10.1016/j.jcf.2016.07.011.
  • Magruder JT, Crawford TC, Grimm JC, Kim B, Shah AS, Bush EL, Higgins RS, Merlo CA. Risk factors for de novo malignancy following lung transplantation. Am J Transplant. 2017 Jan;17(1):227–238. doi:10.1111/ajt.13925.
  • Ohman J, Rexius H, Mjornstedt L, Gonzalez H, Holmberg E, Dellgren G, Hasséus B. Oral and lip cancer in solid organ transplant patients–a cohort study from a Swedish transplant centre. Oral Oncol. 2015 Feb;51(2):146–150. doi:10.1016/j.oraloncology.2014.11.007.
  • Medani S, O’Kelly P, O’Brien KM, Mohan P, Magee C, Conlon P. Bladder cancer in renal allograft recipients: risk factors and outcomes. Transplant Proc. 2014;46(10):3466–3473. doi:10.1016/j.transproceed.2014.06.075.
  • Vajdic CM, van Leeuwen MT, McDonald SP, McCredie MRE, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE. Increased incidence of squamous cell carcinoma of eye after kidney transplantation. J Natl Cancer Inst. 2007;99(17):1340–1342. doi:10.1093/jnci/djm085.
  • Vajdic CM, van Leeuwen MT, Turner JJ, McDonald AM, Webster AC, McDonald SP, Chapman JR, Kaldor JM, Grulich AE. No excess risk of follicular lymphoma in kidney transplant and HIV-related immunodeficiency. Int J Cancer. 2010;127(11):2732–2735. doi:10.1002/ijc.25272.
  • Verran DJ, Mulhearn MH, Dilworth PJ, Balderson GA, Munn S, Chen JW, Fink MA, Crawford MD, McCaughan GW. Nature and outcomes of the increased incidence of colorectal malignancy after liver transplantation in Australasia. Med J Aust. 2013;199(9):610–612. doi:10.5694/mja13.10102.
  • Tessari G, Naldi L, Boschiero L, Cordiano C, Piaserico S, Fortina AB, Cerimele D, La Parola IL, Capuano M, Gotti E, et al. Incidence and clinical predictors of Kaposi’s sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. Eur J Dermatol. 2006 Sep-Oct;16(5):553–557.
  • Triplette M, Crothers K, Mahale P, Yanik EL, Valapour M, Lynch CF, Schabath MB, Castenson D, Engels EA. Risk of lung cancer in lung transplant recipients in the United States. Am J Transplant. 2019 May;19(5):1478–1490. doi:10.1111/ajt.15181.
  • Laprise C, Cahoon EK, Lynch CF, Kahn AR, Copeland G, Gonsalves L, Madeleine MM, Pfeiffer RM, Engels EA. Risk of lip cancer after solid organ transplantation in the United States. Am J Transplant. 2019 Jan;19(1):227–237. doi:10.1111/ajt.15052.
  • Morton LM, Gibson TM, Clarke CA, Lynch CF, Anderson LA, Pfeiffer R, Landgren O, Weisenburger DD, Engels EA. Risk of myeloid neoplasms after solid organ transplantation. Leukemia. 2014 Dec;28(12):2317–2323. doi:10.1038/leu.2014.132.
  • Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10(4):321–322. doi:10.1016/S1470-2045(09)70096-8.
  • Mayer V, Ebbesen P. Persistent viral infections in human carcinogenesis. Eur J Cancer Prev. 1994;3(1):5–14. doi:10.1097/00008469-199401000-00002.
  • Buzzeo BD, Heisey DM, Messing EM; Buzzeo BD, Heisey DM, Messing EM. Bladder cancer in renal transplant recipients. Urology. 1997;50(4):525–528. doi:10.1016/S0090-4295(97)00305-1.
  • Yan L, Chen P, Chen EZ, Gu A, Jiang Z-Y. Risk of bladder cancer in renal transplant recipients: a meta-analysis. Br J Cancer. 2014;110(7):1871–1877. doi:10.1038/bjc.2014.44.
  • Holt CD. Overview of immunosuppressive therapy in solid organ transplantation. Anesthesiol Clin. 2017;35(3):365–380. doi:10.1016/j.anclin.2017.04.001.
  • Sanches MM, Travassos AR, Soares-de-Almeida L. The relationship between immunodepression and the development of skin cancer [A Relação Entre a Imunodepressão e o Desenvolvimento de Cancro Cutâneo]. Acta Med Port. 2017;30:69–72.
  • Chin-Hong PV, Reid GE, Practice A. Human papillomavirus infection in solid organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13590–e13590. doi:10.1111/ctr.13590.
  • Mittal A, Colegio OR. Skin cancers in organ transplant recipients. American J Transplantation. 2017;17(10):2509–2530. doi:10.1111/ajt.14382.
  • Brem R, Li F, Karran P. Reactive oxygen species generated by thiopurine/UVA cause irreparable transcription-blocking DNA lesions. Nucleic Acids Res. 2009 Apr;37(6):1951–1961. doi:10.1093/nar/gkp070.
  • Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation. 1987 Sep;44(3):429–434. doi:10.1097/00007890-198709000-00021.
  • Brand T, Haithcock B. Lung cancer and lung transplantation. Thorac Surg Clin. 2018 Feb;28(1):15–18. doi:10.1016/j.thorsurg.2017.09.003.
  • Chambers DC, Cherikh WS, Goldfarb SB, Hayes D, Kucheryavaya AY, Toll AE, Khush KK, Levvey BJ, Meiser B, Rossano JW, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-fifth adult lung and heart-lung transplant report-2018; focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018;37(10):1169–1183. doi:10.1016/j.healun.2018.07.020.
  • ISHLT adult heart transplantation statistics. 2018. [cited 2020 Jan 20]. Available from: https://ishltregistries.org/registries/slides.asp.
  • de Fijter JW. Cancer and mTOR inhibitors in transplant recipients. Transplantation. 2017;101:45–55.
  • Oweira H, Schmidt J, Helbling D, Petrausch U, Schöb O, Mehrabi A, Giryes A, Elhadedy H, Abdel-Rahman O. Impact of liver transplantation on the risk of second malignant tumors among hepatocellular carcinoma patients. Expert Rev Gastroenterol Hepatol. 2017;11(9):865–869. doi:10.1080/17474124.2017.1355235.
  • Rompianesi G, Ravikumar R, Jose S, Allison M, Athale A, Creamer F, Gunson B, Manas D, Monaco A, Mirza D, et al. Incidence and outcome of colorectal cancer in liver transplant recipients: a national, multicentre analysis on 8115 patients. Liver Int. 2019;39(2):353–360.
  • Heinz-Peer G, Schoder M, Rand T, Mayer G, Mostbeck GH. Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study. Radiology. 1995;195(3):667–671. doi:10.1148/radiology.195.3.7753991.
  • Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017 Dec 21;377(25):2500–2501. doi:10.1056/NEJMc1713444.
  • Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909–1920. doi:10.1016/S0140-6736(16)00561-4.
  • Ordóñez-Mena JM, Schöttker B, Mons U, Jenab M, Freisling H, Bueno-de-Mesquita B, O'Doherty MG, Scott A, Kee F, Stricker BH, et al. Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium. BMC Med. 2016;14:62.
  • Freisling H, Arnold M, Soerjomataram I, O’Doherty MG, Ordóñez-Mena JM, Bamia C, Kampman E, Leitzmann M, Romieu I, Kee F, et al. Comparison of general obesity and measures of body fat distribution in older adults in relation to cancer risk: meta-analysis of individual participant data of seven prospective cohorts in Europe. Br J Cancer. 2017;116(11):1486–1497. doi:10.1038/bjc.2017.106.
  • Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, Scotti L, Jenab M, Turati F, Pasquali E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112(3):580–593. doi:10.1038/bjc.2014.579.
  • Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530–534. doi:10.1038/17401.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.